CAP 2030 : Chart The Future

We are delighted to announce that as part of our strategic roadmap CAP 2030, EMA Pharmaceuticals is entering a new phase of its development to better serve our customers.

Our ambition is to evolve from a European quality leader in sealing solutions for pharmaceutical applications into a truly transatlantic and global partner, with operational capabilities on both sides of the Atlantic.

To support this vision, EMA Pharmaceuticals has initiated the development of operations in the United States through a step-by-step approach that will ultimately replicate our state-of-the-art French manufacturing
processes. The start of our American operations is currently planned for late 2027.

To support our growing activity and key projects with customers across North America, and to prepare EMA Pharma’s operational presence in the region, we are entrusting Mr. Stefan Greife, currently Sales Director, with the role of Vice President Sales North America, effective March 1st.

At the same time, to support our continued expansion in other fast-growing regions, we are delighted to welcome Mr. Ziad Arab as Sales Director. Ziad is a well-known and highly respected professional in the pharmaceutical packaging industry. Ziad will lead EMA Pharma’s commercial activities for all non-American markets, with the mission to further strengthen local partnerships and reinforce EMA’s position as a global quality leader in pharmaceutical sealing solutions. These changes will ensure a smooth transition and continued close support for all our partners.

In parallel, EMA continues to invest strongly in its French operations, further strengthening the manufacturing excellence and quality leadership already recognized by more than 200 pharmaceutical fill-and-finish sites worldwide.

Thank you for your continued trust and partnership. The entire EMA team joins me in looking forward to continuing to support your projects and future developments.

Eric Lebosse de Lannoy